GlassScriptPhysician profile
Roberto Fabricio Diaz
NPI 1851300891
$7,275.72
in general payments reported to CMS, 2019-2025
34 companies · $18.89 in 2025
The $18.89 reported for 2025 was less than what a typical Sleep Medicine (Internal Medicine) provider received nationally (typical 2025 total: $447).
See the full distribution for Sleep Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,254 · 2020: $2,425 · 2021: $831 · 2022: $617 · 2023: $30.94 · 2024: $99.13 · 2025: $18.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $148.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,167.51 | 2019-2022 | |
| Novo Nordisk INC | $1,094.53 | 2019-2022 | |
| Amgen INC. | $446.85 | 2019-2021 | |
| Amarin Pharma, INC. | $405.63 | 2019-2022 | |
| Pfizer INC. | $369.30 | 2019-2021 | |
| Glaxosmithkline, LLC. | $348.91 | 2019-2025 | Bexsero, Rotarix, Pediarix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $341.78 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $314.76 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $292.36 | 2019-2022 | |
| Astellas Pharma US INC | $283.40 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $282.32 | 2019-2021 | |
| Lilly USA, LLC | $262.88 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $261.31 | 2019-2021 | |
| Allergan, INC. | $236.78 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $166.16 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $159.64 | 2019-2022 | |
| Spr Therapeutics, INC | $147.13 | 2022-2024 | Sprint Pns System |
| Abbvie INC. | $110.51 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.83 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $94.96 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $61.24 | 2021 | |
| Esperion Therapeutics, INC. | $55.09 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $41.68 | 2019 | |
| Abbott Laboratories | $34.49 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $30.10 | 2019 | |
| Dexcom, INC. | $29.47 | 2022 | |
| Shire North American Group INC | $20.79 | 2019 | |
| Paratek Pharmaceuticals, INC. | $18.91 | 2022 | |
| Corcept Therapeutics | $18.70 | 2021 | |
| Davol INC. | $17.38 | 2023 | Arista Ah Flexitip |
| Arbor Pharmaceuticals, INC. | $16.34 | 2020 | |
| Eisai INC. | $15.91 | 2020 | |
| Mdd US Operations, LLC | $15.51 | 2019 | |
| Genentech, INC. | $13.56 | 2023 | Vabysmo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.